Background
==========

More than three billion people are at risk of malaria \[[@B1]\]. Despite recent progress in malaria control, there were around 216 million episodes of clinical infection in 2010 \[[@B1]\]. Most malaria deaths, around 655,000 each year, occur from *Plasmodium falciparum* infection in children under five years of age \[[@B1],[@B2]\]. However, the important contribution of *Plasmodium vivax* infection to global malaria morbidity is now also being recognized \[[@B3]-[@B6]\].

For *P. falciparum* malaria, artemisinin-based combination therapy (ACT) is generally recommended by the World Heath Organization (WHO) \[[@B7]\]. Parasite burden and fever are rapidly reduced with ACT and efficacy remains high in most regions \[[@B7]\]. Artemisinin tolerance -- observed as extended parasite clearance times with ACT treatment -- has emerged among *P. falciparum* from the Cambodia--Thailand border areas \[[@B8]-[@B15]\], with some evidence of resistance spreading at the Thailand--Myanmar border \[[@B16]\]. For *P. vivax*, the WHO recommends ACT in areas where chloroquine resistance has emerged \[[@B7]\]; most notably Indonesia, though there are also reports from further east in the Malay archipelago to Papua New Guinea and Vietnam as well as from South America and Oceania \[[@B17],[@B18]\]. Using ACT in areas co-endemic for *P. falciparum* and *P. vivax* has also been suggested as a strategy to overcome difficulties in differential diagnosis and in cases of mixed infection \[[@B17],[@B19],[@B20]\].

Pyronaridine-artesunate (PA) (3:1 ratio) is a novel ACT indicated for the treatment of acute uncomplicated *P. falciparum* or *P. vivax* malaria \[[@B15],[@B21]-[@B25]\]. *In vitro* studies indicate potent activity against recent isolates of multidrug-resistant strains of both *P. falciparum* and *P. vivax* from Papua, Indonesia \[[@B26]\], against Kenyan *P. falciparum* isolates \[[@B27]\], and against around half of chloroquine-resistant *P. falciparum* strains from the China--Myanmar border area \[[@B28]\]. The PA clinical development programme included two Phase II trials and three Phase III trials in children and adults from Africa and Asia with uncomplicated *P. falciparum* malaria \[[@B15],[@B22],[@B24],[@B25]\], as well as one comparative Phase III trial in children and adults with uncomplicated *P. vivax* infection \[[@B23]\]. The programme incorporated parallel development of an adult tablet and a paediatric granule formulation \[[@B22]\], shown in a Phase II study to display similar bioavailability \[[@B24]\]. In all four Phase III studies, PA efficacy was non-inferior to the comparator anti-malarial drugs and PA was generally well tolerated \[[@B15],[@B22],[@B23],[@B25]\].

The objective of this paper was to evaluate PA safety outcomes by integrating individual patient data from two Phase II and four Phase III randomized clinical trials \[[@B15],[@B22]-[@B25]\]. Efficacy outcomes for PA in uncomplicated *P. falciparum* malaria were examined descriptively across the three Phase III trials that included patients with this infection \[[@B15],[@B22],[@B25]\].

Methods
=======

Ethics statement
----------------

The clinical trials were conducted in accordance with the Declaration of Helsinki (Tokyo 2004), Good Clinical Practice and applicable regulations. Trial protocols were approved by the independent ethics committee of each study centre. All patients or their guardians provided informed written or witnessed oral consent; assent was required from children able to understand the study.

Source data
-----------

Individual patient data were integrated from six PA randomized clinical trials, two Phase II studies and four Phase III studies, conducted in sub-Saharan Africa, Southeast Asia and India between 2005 and 2008 (Table  [1](#T1){ref-type="table"}) \[[@B15],[@B22]-[@B25]\]. Further details of the trial protocols are supplied in the published reports \[[@B15],[@B22]-[@B25]\].

###### 

Summary of pyronaridine-artesunate Phase II/III randomized clinical trials included in the integrated analysis

  **Protocol**                   **SP-C-002-05**   **SP-C-003-05\[**\[[@B24]\]**\]**   **SP-C-004-06\[**\[[@B15]\]**\]**   **SP-C-005-06\[**\[[@B25]\]**\]**   **SP-C-007-07\[**\[[@B22]\]**\]**   **SP-C-006-06\[**\[[@B23]\]**\]**
  ------------------------------ ----------------- ----------------------------------- ----------------------------------- ----------------------------------- ----------------------------------- -----------------------------------
  Phase                          II                II                                  III                                 III                                 III                                 III
  Region/country                 SE Asia, Africa   Gabon                               SE Asia, India, Africa              Africa, SE Asia                     Africa, SE Asia                     SE Asia, India
  Year                           2005--2006        2006                                2007--2008                          2007--2008                          2007--2008                          2007--2008
  Design                         DB/MC/DF          OL/DF                               OL/MC/CM                            DB/DD/MC/CM                         OL/MC/CM                            DB/DD/MC/CM
  Pathogen                       *P. falciparum*   *P. falciparum*                     *P. falciparum*                     *P. falciparum*                     *P. falciparum*                     *P. vivax*
  Parasite count^a^, μL^-1^      1000--100,000     1000--200,000                       1000--100,000                       1000--100,000                       1000--200,000                       ≥250
  Patient age, years             15--60            2--14                               3--60                               3--60                               ≤12                                 3--60
  Patient weight, kg             35--75            10--40                              20--90                              20--90                              ≥5-- \<25                           20--90
  PA target dose^b^, mg/kg/day   6:2, 9:3, 12:4    6:2, 9:3, 12:4 Granule: 9:3         7.2:2.4--13.8:4.6                   7.2:2.4--13.8:4.6                   6.7:2.2--13.3:4.4                   7.2:2.4--13.8:4.6
  PA dose form                   Tablet            Tablet and granule                  Tablet                              Tablet                              Granule                             Tablet
  Comparator                     --                --                                  MQ + AS                             AL                                  AL^b^                               CQ

Study design: CM, comparative; DB, double-blind; DD, double-dummy; DF, dose-finding; MC, multi-centre; OL, open label.

Comparators: MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; CQ, chloroquine.

^a^ Asexual parasite count for *P. falciparum* and including at least 50% asexual parasites for *P. vivax.*

^b^ Crushed tablets.

Details of the studies included in this analysis are summarized in Table  [1](#T1){ref-type="table"}. The two Phase II studies were non-comparative; one was a dose escalation study to examine the safety and pharmacokinetics of the PA tablet and granule formulations in children with *P. falciparum* (SP-C-003-05) \[[@B24]\], the other was a dose ranging study (SP-C-002-05) of PA tablets in adults with *P. falciparum* malaria. Of the four Phase III studies, three were conducted in subjects with *P. falciparum*\[[@B15],[@B22],[@B25]\], two studies used PA tablets \[[@B15],[@B25]\], and one the PA granule formulation \[[@B22]\]. The remaining Phase III study included subjects with *P. vivax* malaria \[[@B23]\]. All four Phase III studies were non-inferiority studies against comparators recommended as first-line anti-malarial therapy in the relevant countries. The non-inferiority margin was 5% in the two *P. falciparum* tablet studies that included both children and adults (SP-C-004-06, SP-C-005-06), and 10% in the paediatric granule *P. falciparum* study (SP-C-007-07) and the *P. vivax* study (SP-C-006-06).

Treatments
----------

Pyronaridine-artesunate (Shin Poong Pharmaceutical Company Ltd, Ansan, South Korea) was supplied as tablets (180:60 mg per tablet) or as a paediatric granule formulation presented in sachets (60:20 mg per sachet). In the Phase III studies, PA was given once daily for three days (day 0, 1, 2), dosed by body weight as follows, for tablets: 20--25 kg one tablet, 26--44 kg two tablets, 45--64 kg three tablets, 65--90 kg four tablets, i e, 7.2:2.4 to 13.8:4.6 mg/kg/dose; and for granules, ≥5-- \<9 kg one sachet, 9-- \<17 kg two sachets, 17-- \<25 kg three sachets, i e, 6.7:2.2 to 13.3:4.4 mg/kg/dose.

The comparators in the PA Phase III *P. falciparum* studies were dosed by body weight. Artemether-lumefantrine (AL) was given twice daily for three days, at 0.9:5.3 to 2.4:14.4 mg/kg/dose for tablets in SP-C-005-06 and 1.3:8.0 to 4.0:24.0 mg/kg/dose for crushed tablets in SP-C-007-07. Dosing of AL was with or without food based on local practices. Mefloquine + artesunate (MQ + AS) was given as a loose combination, once daily for three days at 5.6:2.2 to 12.5:5.0 mg/kg/dose in study SP-C-004-06. In the Phase III *P. vivax* study (SP-C-006-06), the comparator chloroquine (CQ) was given once daily for three days at a daily dose in children of 10 mg/kg on days 0 and 1 and 5 mg/kg on day 2 and for adults of 620 mg on days 0 and 1 and 310 mg on day 2.

Patients and procedures
-----------------------

Patients and procedures are described in detail elsewhere \[[@B15],[@B22]-[@B25]\]. In brief, patients of either gender were eligible if they had *P. falciparum* mono-infection, or in SP-C-006-06 *P. vivax* mono-infection, in all cases microscopically confirmed within defined limits (Table  [1](#T1){ref-type="table"}), with fever or a history of fever while meeting age/body weight criteria for each study (Table  [1](#T1){ref-type="table"}). Patients were excluded if they had significant co-morbid illness, recent anti-malarial therapy, known hypersensitivity to study drugs, evidence of severe malnutrition, if they were pregnant (test required) or breastfeeding, or had participated previously in a PA clinical trial.

At screening, a medical history was taken and a physical examination performed. All enrolled patients were hospitalized from day 0 to 3. Follow-up assessments were at days 7, 14, 21, 28, 35 and 42. Vital signs and malaria signs/symptoms were monitored throughout the study. Temperature was taken at screening, every 8 h over ≥72 h following the first dose or until two normal readings between 7 and 25 h apart, then at each visit or as clinically indicated. Venous blood samples were taken for clinical biochemistry, haematology and urinalysis testing and 12-lead electrocardiographs were performed at screening and then at intervals as specified in the protocol.

Parasitological assessments were performed according to WHO guidelines \[[@B29]\]. Giemsa-stained thick blood slides were prepared before each dose, every 8 h (±1 h) following first dose administration for ≥72 h or until parasite clearance (two consecutive negative readings 7 to 25 h apart), and at subsequent visits. For *P. falciparum*, asexual and gametocyte parasite counts were performed separately; for *P. vivax* asexual and gametocyte parasite counts were recorded separately at screening and total parasite counts recorded at all other assessments. Thin blood slides were prepared for parasite identification at screening and from day 7 at all follow-up visits. In the *P. falciparum* Phase III studies, recrudescence was determined by PCR genotyping using *P. falciparum* genes *msp* 1, *msp* 2, and *glurp*; defined as at least one matching allelic band in all markers between baseline and post-day-7 samples \[[@B30],[@B31]\].

Outcomes
--------

Safety outcomes were adverse event incidence and severity (categorized using MedDRA version 10.1), laboratory abnormalities (graded according to the Division of Microbiology and Infectious Diseases Toxicity Scale), and electrocardiograph abnormalities.

Efficacy outcomes were integrated for the Phase III *P. falciparum* studies only and were defined according to WHO methods \[[@B29]\]. The primary efficacy outcome was day-28 PCR-corrected adequate clinical and parasitological response (ACPR), defined as clearance of asexual parasitaemia without recrudescence or previous treatment failure. Day-28 uncorrected ACPR was a secondary endpoint.

Secondary efficacy endpoints were parasite clearance time (time from first dose to asexual aparasitaemia for two consecutive negative readings 7--25 h apart); fever clearance time (time from first dose to apyrexia for two consecutive normal temperature readings 7--25 h apart); and the proportion of subjects aparasitic and proportion apyretic at day 1 (24 h after the first dose), day 2 (48 h after the first dose), and day 3 (72 h after the first dose). The proportion of patients with gametocytes at each assessment was an exploratory endpoint.

Statistical methods
-------------------

The safety analysis included data from all Phase II and Phase III studies and was conducted on the safety population, i e, all patients who had received any amount of study drug. Descriptive statistics were provided for safety outcomes.

The efficacy analysis included data from the Phase III *P. falciparum* trials and in the integrated analysis was conducted primarily on the intent-to-treat (ITT) population, i e, all randomized patients with *P. falciparum* malaria who received any amount of study medication. This definition was consistent across all the Phase III *P. falciparum* studies. Descriptive statistics were provided for efficacy outcomes.

Descriptive sub-group analyses were performed for day-28 PCR-corrected ACPR for the ITT population as follows: region (Asia, Africa); age (\<5, 5--12, \>12-- \<18, ≥18 years); gender (male, female); weight (\<17, ≥17-- \<25, ≥25 kg); previous malaria episode (yes, no); number of previous malaria episodes in the last 12 months (0, 1, \>1); baseline parasitaemia (≤5,000, \>5,000--10,000, \>10,000 μL^-1^); PA formulation (granule, tablet); and PA actual dose (≤8.5:2.8, \>8.5:2.8--9.5:3.2, \>9.5:3.2--11.0:3.7, \>11.0:3.7 mg/kg/day).

Post-hoc analyses of time to recrudescence and time to re-infection conducted using Kaplan-Meier estimates (log-rank test) were conducted for the integrated analysis; subjects without the event were censored at the last available parasite assessment date.

Kaplan-Meier estimates were used to evaluate parasite clearance time and fever clearance time. Subjects without parasite or fever clearance within 72 h after the first treatment dose were censored at that time point. An additional analysis of parasite clearance time in Cambodia (Pailin at the Cambodia--Thailand border) *versus* Thailand (Mae Sot and Mae Ramat) was performed without censoring at 72 h. The proportion of subjects with parasite clearance and the proportion of subjects with fever clearance on days 1, 2 and 3 were calculated using Kaplan-Meier estimates. Log~10~ area under the curve (AUC) for gametocyte density was calculated in count · day/μL based on a log~10~ transformation. Statistical analysis was performed using SAS (Version 9.1).

Results
=======

Patients
--------

Overall, 2,817 patients were randomized to PA and 1,254 to comparators (MQ + AS, AL and CQ). Two subjects did not receive PA and were excluded from the safety population (*n* = 2,815) (Table  [2](#T2){ref-type="table"}). A similar proportion of patients in the PA group (14.4% \[405/2,815\]) discontinued treatment as for comparators (17.6% \[221/1,254\]). In the efficacy (ITT) population, 2,052 subjects with *P. falciparum* malaria were treated with PA and 1,026 with comparators (MQ + AS or AL) (Table  [2](#T2){ref-type="table"}). Subject disposition for the efficacy ITT population was similar to that of the safety population (Table  [2](#T2){ref-type="table"}).

###### 

Subject disposition

             **Subjects**             **PA safety**   **PA efficacy (ITT)**   **MQ + AS safety/efficacy**   **AL safety/efficacy**   **CQ safety**   **All comparators safety**^**a**^
  ---------------------------------- --------------- ----------------------- ----------------------------- ------------------------ --------------- -----------------------------------
              Treated^b^                  2815                2052                        423                        603                  228                      1254
        Completed treatment^c^         2773 (98.5)         2017 (98.3)                418 (98.8)                  587 (97.3)          220 (96.5)                1225 (97.7)
           Completed study             2410 (85.6)         1748 (85.2)                357 (84.4)                  489 (81.1)          187 (82.0)                1033 (82.4)
            Discontinued:              405 (14.4)          304 (14.8)                  66 (15.6)                  114 (18.9)           41 (18.0)                221 (17.6)
             Adverse event              46 (1.6)            32 (1.6)                    4 (0.9)                    10 (1.7)             2 (0.9)                  16 (1.3)
           Consent withdrawn            26 (0.9)            19 (0.9)                    6 (1.4)                    11 (1.8)             5 (2.2)                  22 (1.8)
    Insufficient therapeutic effect     11 (0.4)                0                          0                          0                    0                         0
           Lost to follow-up            99 (3.5)            69 (3.4)                   25 (5.9)                    10 (1.7)            12 (5.3)                  47 (3.7)
          Protocol violation             9 (0.3)             4 (0.2)                       0                       1 (0.2)                 0                      1 (0.1)
           Malaria infection            186 (6.6)           174 (8.5)                  29 (6.9)                   78 (12.9)            21 (9.2)                 128 (10.2)
                 Other                  28 (1.0)             6 (0.3)                    2 (0.5)                    4 (0.7)              1 (0.4)                   7 (0.6)

Data are n (%).

PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; CQ, chloroquine.

^a^ For comparators, MQ + AS, AL and CQ were included in the safety analysis; MQ + AS and AL in the efficacy analysis.

^b^ Received at least one dose of study medication.

^c^ Received all planned doses of study medication.

In the PA group (safety population), 91.9% (2,587/2,815) of patients were treated for *P. falciparum* and 8.1% (228/2,815) for *P. vivax* malaria, 49.3% (1,389/2,815) of subjects were from Asia, 50.7% (1,426/2,815) from Africa and mean patient age was 20.6 years (Table  [3](#T3){ref-type="table"}). Overall in the safety population, the PA group and the combined comparators group were well balanced for baseline demographic and clinical characteristics (Table  [3](#T3){ref-type="table"}). However, for individual comparators, integration of the data led to imbalances in patient age and the regions from which patients were recruited because of the different study entry criteria (Table  [3](#T3){ref-type="table"}).

###### 

Patient baseline characteristics

  **Characteristic**                                                     **PA safety**^**a**^      **PA efficacy (ITT)**^**a**^   **MQ + AS safety/efficacy**    **AL safety/efficacy**           **CQ safety**          **All comparators safety**^**a**^
  ------------------------------------------------------------------- --------------------------- ------------------------------ ----------------------------- --------------------------- ---------------------------- -----------------------------------
  Female gender, n (%)                                                        956 (34.0)                    751 (36.6)                     93 (22.0)                   288 (47.8)                   64 (28.1)                       445 (35.5)
  Mean age, years (SD) \[range\]                                       20.6 (12.9) \[0.3--60.4\]    18.6 (12.6) \[0.3--60.4\]      25.6 (12.5) \[5.5--59.7\]    14.6 (11.3) \[0.3--57.0\]   26.6 (10.9) \[7.0--58.0\]        20.5 (12.9) \[0.3--59.7\]
  Age category, years, n (%)                                                                                                                                                                                                              
    ≤1 year                                                                     9 (0.3)                      9 (0.4)                           0                         3 (0.5)                        0                             3 (0.2)
    \>1-- \<5                                                                  173 (6.1)                    150 (7.3)                          0                        68 (11.3)                       0                            68 (5.4)
    5--12                                                                     704 (25.0)                    656 (32.0)                     61 (14.4)                   274 (45.4)                    9 (3.9)                        344 (27.4)
    \>12-- \<18                                                               401 (14.2)                    316 (15.4)                     53 (12.5)                    92 (15.3)                   28 (12.3)                       173 (13.8)
    ≥18                                                                       1528 (54.3)                   921 (44.9)                    309 (73.0)                   166 (27.5)                   191 (83.8)                      666 (53.1)
  Region, n (%)^b^                                                                                                                                                                                                                        
    Africa                                                                    1426 (50.7)                  1223 (59.6)                     79 (18.7)                   531 (88.1)                       0                           610 (48.6)
    Asia                                                                      1389 (49.3)                   829 (40.4)                    344 (81.3)                    72 (11.9)                   228 (100)                       644 (51.4)
  Mean body weight, kg (SD) \[range\]                                  42.1 (16.5) \[6.0--89.5\]    39.5 (17.1) \[6.0--89.5\]     47.3 (12.1) \[20.0--75.0\]    34.6 (18.1) \[7.2--86.0\]   49.4 (10.2) \[20.0--80.0\]       41.6 (16.5) \[7.2--86.0\]
  Malaria in last 12 months, n (%)                                            *n* = 2551                    *n* = 2045                     *n* = 423                    *n* = 600                   *n* = 228                       *n* = 1251
    0                                                                         1431 (56.1)                  1064 (52.0)                    258 (61.0)                   269 (44.8)                   123 (53.9)                      650 (52.0)
    1                                                                         498 (19.5)                    444 (21.7)                     92 (21.7)                   116 (19.3)                   58 (25.4)                       266 (21.3)
    \>1                                                                       622 (24.4)                    537 (26.3)                     73 (17.3)                   215 (35.8)                   47 (20.6)                       335 (26.8)
  *P. falciparum* parasitaemia, μL^-1^, n (%)^c^                                                                                                                                                                                          
    ≤5000                                                                     691 (26.8)                    521 (25.4)                    113 (26.7)                   161 (26.7)                       --                          274 (26.7)
    \>5000--10,000                                                            394 (15.3)                    293 (14.3)                     72 (17.0)                    81 (13.5)                       --                          153 (14.9)
    \>10,000                                                                  1497 (58.0)                  1238 (60.3)                    238 (56.3)                   360 (59.8)                       --                          598 (58.3)
  *P. vivax* geometric mean asexual parasitaemia, μL^--1^ \[range\]      6914.8 \[466--92500\]                  --                            --                           --                 6145.8 \[366--77035\]                     --
  Mean haemoglobin, g/dL (SD)                                                 11.9 (2.0)                    11.8 (2.0)                    12.1 (2.0)                   11.5 (1.9)                   12.3 (1.8)                      11.9 (1.9)

PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; CQ, chloroquine.

^a^ The safety analysis included data from all Phase II and Phase III studies. The efficacy analysis included data from the Phase III *P. falciparum* trials. For comparators, MQ + AS, AL and CQ were included in the safety analysis; MQ + AS and AL in the efficacy analysis.

^b^ All subjects from African centres were of Black ethnicity except one in the AL group who was Asian/Oriental; all patients from Asian centres were of Asian/Oriental ethnicity.

^c^ Baseline *P. falciparum* parasite count was not available for five patients in the PA group and one patient in the AL group.

Safety
------

In the safety population, medication was taken as planned for 98.9% (2,785/2,815) of patients receiving PA and 98.6% (1,236/1,254) of those receiving comparators. All drug treatments were generally well tolerated. The number of patients with at least one treatment-emergent adverse event was similar for PA (57.2% \[1,611/2,815\]) and comparators (51.5% \[646/1,254\]), as was the number of patients thought to have adverse events related to drug therapy: 25.2% (708/2,815) and 25.5% (320/1,254), respectively. The nature and incidence of adverse events due to any cause was similar for PA *versus* combined comparators (Table  [4](#T4){ref-type="table"}). The most common adverse events were headache (10.6% PA; 9.9% comparators), cough (5.9% PA; 5.6% comparators) and anaemia (4.5% PA; 2.9% comparators) (Table  [4](#T4){ref-type="table"}).

###### 

**Treatment-emergent adverse events of any cause occurring in ≥2**% **of all subjects in any treatment group (safety population)**

  **Adverse event**                                     **PA**        **MQ + AS**       **AL**            **CQ**             **All comparators**
  ----------------------------------------------------- ------------- ----------------- ----------------- ------------------ ---------------------
  Any adverse event                                     1611 (57.2)   190 (44.9)        384 (63.7)        72 (31.6)          646 (51.5)
  **Blood and lymphatic system disorders**                                                                                    
  Anaemia                                               128 (4.5)     17 (4.0)          18 (3.0)          1 (0.4)            36 (2.9)
  Basophilia                                            9 (0.3)       9 (2.1)           1 (0.2)           0                  10 (0.8)
  Eosinophilia                                          101 (3.6)     5 (1.2)           27 (4.5)          4 (1.8)            36 (2.9)
  Lymphocytosis                                         21 (0.7)      0                 [16 (2.7)]{.ul}   0                  16 (1.3)
  Neutropenia                                           55 (2.0)      0                 [27 (4.5)]{.ul}   0                  27 (2.2)
  **Gastrointestinal disorders**                                                                                              
  Abdominal pain                                        98 (3.5)      7 (1.7)           31 (5.1)          2 (0.9)            40 (3.2)
  Diarrhoea                                             41 (1.5)      9 (2.1)           6 (1.0)           2 (0.9)            17 (1.4)
  Vomiting                                              124 (4.4)     9 (2.1)           23 (3.8)          7 (3.1)            39 (3.1)
  **General disorders**                                                                                                       
  Fatigue                                               49 (1.7)      6 (1.4)           3 (0.5)           [11 (4.8)]{.ul}    20 (1.6)
  Influenza-like illness                                49 (1.7)      0                 21 (3.5)          0                  21 (1.7)
  Pyrexia                                               66 (2.3)      4 (0.9)           18 (3.0)          2 (0.9)            24 (1.9)
  **Infections and infestations**                                                                                             
  Bronchitis                                            52 (1.8)      6 (1.4)           12 (2.0)          3 (1.3)            21 (1.7)
  Nasopharyngitis                                       74 (2.6)      11 (2.6)          8 (1.3)           6 (2.6)            25 (2.0)
  Rhinitis                                              19 (0.7)      2 (0.5)           12 (2.0)          0                  14 (1.1)
  Upper RTI                                             100 (3.6)     4 (0.9)           31 (5.1)          0                  35 (2.8)
  Urinary tract infection                               34 (1.2)      3 (0.7)           12 (2.0)          1 (0.4)            16 (1.3)
  **Investigations**                                                                                                          
  AST increased                                         63 (2.2)      1 (0.2)           14 (2.3)          0                  15 (1.2)
  Blood albumin decreased                               21 (0.7)      0                 [16 (2.7)]{.ul}   0                  16 (1.3)
  Blood CPK increased                                   26 (0.9)      4 (0.9)           3 (0.5)           8 (3.5)            15 (1.2)
  Blood glucose decreased                               33 (1.2)      0                 [19 (3.2)]{.ul}   0                  19 (1.5)
  ECG QT prolongation                                   6 (0.2)       5 (1.2)           1 (0.2)           6 (2.6)            12 (1.0)
  Eosinophil count increased                            58 (2.1)      6 (1.4)           2 (0.3)           0                  8 (0.6)
  Platelet count increased                              59 (2.1)      3 (0.7)           20 (3.3)          0                  23 (1.8)
  **Metabolism and nutrition disorders**                                                                                      
  Anorexia                                              85 (3.0)      13 (3.1)          10 (1.7)          10 (4.4)           33 (2.6)
  **Musculoskeletal and connective tissue disorders**                                                                         
  Myalgia                                               107 (3.8)     19 (4.5)          1 (0.2)           [21 (9.2)]{.ul}    41 (3.3)
  **Nervous system disorders**                                                                                                
  Dizziness                                             39 (1.4)      [28 (6.6)]{.ul}   1 (0.2)           6 (2.6)            35 (2.8)
  Headache                                              297 (10.6)    44 (10.4)         46 (7.6)          [34 (14.9)]{.ul}   124 (9.9)
  **Respiratory, thoracic and mediastinal disorders**                                                                         
  Cough                                                 167 (5.9)     10 (2.4)          [55 (9.1)]{.ul}   5 (2.2)            70 (5.6)

Data are n (%). PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; CQ, chloroquine; RTI, respiratory tract infection; AST aspartate aminotransferase; CPK, creatine phosphokinase; ECG, electrocardiograph.

Values underlined are for adverse events occurring in ≥2% of patients in one group *versus* any other group.

Serious adverse events occurred in 0.6% (18/2,815) of patients in the PA group and in 0.4% (5/1,254) in the combined comparators. There were no deaths. One patient in the PA group had two serious adverse events that were considered treatment-related (hepatic enzyme increased and abortion incomplete) and one patient receiving MQ + AS had two treatment-related serious adverse events (convulsion and grand mal convulsion). All other serious adverse events were considered not to be related to treatment: in the PA group there were two cases each of pyrexia, malaria, typhoid fever and urinary tract infection, and one case each of anaemia, cardiac failure, abdominal pain, limb abscess, cholera, paronychia, parotitis, pneumonia, acute pyelonephritis, wound infection, abortion complete and depression; for comparators there were two cases of cerebral malaria and one of immunosuppression.

Overall, adverse events leading to study withdrawal occurred in 1.6% (44/2,815) of patients in the PA group and 1.0% (13/1,254) in the comparator group; vomiting was the reason in 1.1% (32/2,815) and 0.9% (11/1,254) of cases, respectively. In the PA group, other reasons for study withdrawal were *P. falciparum* infection (0.3%; 9/2,815), malaria (0.1%; 3/2,815) and one case each of nausea and fatigue. In the comparator group there were two cases of cerebral malaria (0.2%) leading to study withdrawal. Of the patients who were withdrawn from the study because of an adverse event, drug treatment was discontinued in 2.2% (27/1,254) of patients in the PA group (26 instances of vomiting, one of nausea, one of malaria) and in 1.0% (12/1,254) of patients receiving comparators (10 vomiting, two cerebral malaria).

There were no major differences between PA and comparators in haematology parameters over the course of the study (Figure  [1](#F1){ref-type="fig"}). For all treatment groups, there was a small decrease in haemoglobin concentration on day 3 (mean \<1 g/dL) with recovery to baseline levels by day 28, and corresponding changes in haematocrit and red blood cells. Proportional decreases in neutrophils from baseline were associated with mean proportional increases in lymphocytes and eosinophils. Platelet counts were low at baseline and had increased by day 7 in all treatment groups. There were no clinically meaningful changes from baseline for white blood cells, monocytes or basophils in any treatment group.

![**Changes from baseline in haematology parameters in patients receiving pyronaridine-artesunate or combined comparators (safety population).** NB: Day-28 values are available for the *Plasmodium vivax* study only \[[@B23]\].](1475-2875-12-70-1){#F1}

No clinically important changes from baseline were observed in total bilirubin, alkaline phosphatase, creatinine, albumin, creatine kinase, urea, sodium, potassium, glucose or blood urea nitrogen in any treatment group. In the PA group, both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were increased on day 3 and day 7 *versus* baseline, and normalized by day 28 (Figure  [2](#F2){ref-type="fig"}). In the PA group, treatment-emergent Grade 3/4 toxicities for ALT were recorded for 0.4% (11/2,750) of patients on day 3 and 0.9% (24/2,709) on day 7; for AST the incidence was 0.5% (13/2,757) and 0.3% (9/2,711), respectively. For comparators, in the MQ + AS group 0.2% (1/404) of patients had an ALT Grade 3 toxicity on day 7. In the AL group, 0.2% (1/582) of patients had an ALT Grade 4 toxicity on day 3, and for AST 0.5% (3/583) had Grade 3 toxicity on day 3 and 0.2% (1/581) on day 7. Only one patient in the PA group had a serious adverse event related to a Grade 3/4 biochemistry value, hepatic enzyme increased: Grade 3 AST and ALT values on day 7 (295 U/L and 272 U/L, respectively), decreasing to near normal levels by day 28 (54 U/L, 25 U/L, respectively); total bilirubin was normal at all assessments; ALP was normal except for a Grade 1 toxicity on day 7 (168 U/L). The proportion of patients with ALT and/or AST \>3x the upper limit of normal (ULN) plus peak total bilirubin \>2xULN in the PA group was 0.2% (7/2,815) *versus* 0.3% (2/603) for AL; one of these patients receiving PA also had a clinically important increase in ALP. There were no cases in the MQ + AS or CQ groups. No clinically important changes were recorded for urine glucose, protein and blood screening.

![**Changes from baseline in liver enzymes and total bilirubin in patients receiving pyronaridine-artesunate or combined comparators (safety population).** NB: Day-28 values are available for the *Plasmodium vivax* study only \[[@B23]\].](1475-2875-12-70-2){#F2}

The incidence of treatment-emergent clinically important abnormal electrocardiograph results was 1.1% (30/2,752) for PA, 0.7% (3/417) for MQ + AS, 0.3% (2/588) for AL and 2.7% (6/222) for CQ. An adverse event of QT interval prolongation was recorded for 0.2% (6/2,815) of patients receiving PA, 1.2% (5/423) receiving MQ + AS, 0.2% (1/603) receiving AL and 2.6% (6/228) receiving CQ. The proportion of patients with an adverse event of bradycardia was 1.1% (31/2,815) for PA and 0.8% (5/603) for AL with no cases in the MQ + AS or CQ groups. No electrocardiograph abnormality required drug discontinuation or withdrawal from the study.

Efficacy
--------

Efficacy was evaluated in an integrated analysis of the Phase III *P. falciparum* studies SP-C-004-06 \[[@B15]\] SP-C-005-06 \[[@B25]\] and SP-C-007-07 \[[@B22]\]. Day-28 PCR-corrected ACPR for PA was 93.6% (\[1,921/2,052\] 95% CI 92.6, 94.7) in the ITT population and 98.5% (\[1,852/1,880\] 95% CI 98.0, 99.1) in the PP population; similar to comparators (Figure  [3](#F3){ref-type="fig"}A). For day-28 uncorrected ACPR, there was no difference between PA and comparators in the ITT or PP populations (Figure  [3](#F3){ref-type="fig"}B).

![**Day-28 adequate clinical and parasitological response (ACPR): A) PCR-corrected; B) uncorrected.** Two-sided 95% confidence intervals (Wald) were adjusted for study.](1475-2875-12-70-3){#F3}

Sub-group analysis provided similar day-28 PCR-corrected ACPR rates (ITT population) regardless of region, age group, gender, weight, previous malaria, number of episodes of malaria in the last 12 months, or baseline parasitaemia (Table  [5](#T5){ref-type="table"}). There was no difference in day-28 PCR-corrected ACPR (ITT population) between the PA granule and tablet formulations: 93.8% (\[333/355\] 95% CI 91.3, 96.3) and 93.6% (\[1,588/1,697\] 95% CI 92.4, 94.7), respectively. Efficacy was similar across the actual PA dose groups: 92.2% (\[365/396\] 95% CI 89.5, 94.8) for ≤8.5:2.8 mg/kg/day; 93.9% (\[512/545\] 95% CI 91.9, 96.0) for \>8.5:2.8--9.5:3.2 mg/kg/day; 94.0% (\[616/655\] 95% CI 92.2, 95.9) for \>9.5:3.2--11.0:3.7 mg/kg/day; and 93.9% (\[428/456\] 95% CI 91.6, 96.1) for \>11.0:3.7 mg/kg/day.

###### 

**Descriptive sub-group analysis of day-28 PCR-corrected ACPR for*Plasmodium falciparum*(intent-to-treat population)**

  **Sub-group**                           **PA**      **MQ + AS**         **AL**                                  
  --------------------------------------- ----------- ------------------- --------- ------------------- --------- -------------------
  **Region**                                                                                                       
  Asia                                    760/829     91.7 (89.8, 93.6)   310/344   90.1 (86.9, 93.3)   64/72     88.9 (81.5, 96.3)
  Africa                                  1161/1223   94.9 (93.7, 96.2)   77/79     97.5 (93.9, 100)    496/531   93.4 (91.3, 95.5)
  **Age group, years**                                                                                             
  \<5                                     145/159     91.2 (86.7, 95.6)   --        --                  63/71     88.7 (81.2, 96.3)
  5--12                                   621/656     94.7 (92.9, 96.4)   60/61     98.4 (95.1, 100)    255/274   93.1 (90.0, 96.1)
  \>12-- \<18                             297/316     94.0 (91.4, 96.6)   52/53     98.1 (94.3, 100)    86/92     93.5 (88.3, 98.6)
  ≥18                                     858/921     93.2 (91.5, 94.8)   275/309   89.0 (85.5, 92.5)   156/166   94.0 (90.3, 97.6)
  **Gender**                                                                                                       
  Male                                    1213/1301   93.2 (91.9, 94.6)   299/330   90.6 (87.4, 93.8)   293/315   93.0 (90.2, 95.8)
  Female                                  708/751     94.3 (92.6, 95.9)   88/93     94.6 (90.0, 99.3)   267/288   92.7 (89.7, 95.7)
  **Weight, kg**                                                                                                   
  \<17                                    170/188     90.4 (86.2, 94.7)   --        --                  84/94     89.4 (83.0, 95.7)
  17-- \<25                               385/401     96.0 (94.1, 97.9)   38/39     97.4 (92.2, 100)    159/171   93.0 (89.1, 96.8)
  ≥25                                     1366/1463   93.4 (92.1, 94.6)   349/384   90.9 (90.9, 93.8)   317/338   93.8 (91.2, 96.4)
  **Previous malaria**                                                                                             
  No                                      828/894     92.6 (90.9, 94.3)   199/220   90.5 (86.5, 94.4)   187/206   90.8 (86.8, 94.8)
  Yes                                     1093/1157   94.5 (93.1, 95.8)   188/203   92.6 (89.0, 96.2)   373/397   94.0 (91.6, 96.3)
  **Malaria in last 12 months**                                                                                    
  None                                    976/1064    91.7 (90.1, 93.4)   232/258   89.9 (86.2, 93.6)   243/269   90.3 (86.8, 93.9)
  1 episode                               420/444     94.6 (92.5, 96.7)   84/92     91.3 (85.4, 97.2)   111/116   95.7 (92.0, 99.4)
  \>1 episode                             519/537     96.6 (95.1, 98.2)   71/73     97.3 (93.4, 100)    203/215   94.4 (91.3, 97.5)
  **Baseline parasitaemia, μL**^**-1**^                                                                            
  ≤5000                                   487/521     93.5 (91.3, 95.6)   102/113   90.3 (84.7, 95.8)   150/161   93.2 (89.2, 97.1)
  \>5000--10,000                          275/293     93.9 (91.1, 96.6)   64/72     88.9 (81.5, 96.3)   78/81     96.3 (92.1, 100)
  \>10,000                                1159/1238   93.6 (92.3, 95.0)   221/238   92.9 (89.6, 96.2)   332/360   92.2 (89.4, 95.0)

--, no data available. PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine.

Two-sided confidence intervals (Wald) were adjusted for study.

Kaplan-Meier estimates of *P. falciparum* recrudescence rate and re-infection rate are shown in Figure  [4](#F4){ref-type="fig"}. Both the recrudescence rate (Figure  [4](#F4){ref-type="fig"}A) and the re-infection rate (Figure  [4](#F4){ref-type="fig"}B) with PA were intermediate between MQ + AS and AL.

![***Plasmodium falciparum*A) recrudescence rate B) re-infection rate.** Kaplan-Meier survival plot for the integrated efficacy analysis (intent-to-treat population).](1475-2875-12-70-4){#F4}

The majority of patients in all treatment groups had *P. falciparum* clearance by day 2 (Table  [6](#T6){ref-type="table"}). Median parasite clearance time for *P. falciparum* (ITT population) was 24.1 h with PA, 31.9 h with MQ + AS, and 24.0 h with AL (Table  [6](#T6){ref-type="table"}; Figure  [5](#F5){ref-type="fig"}A). Median parasite clearance time was extended for all treatments in Asian *versus* African centres (Table  [6](#T6){ref-type="table"}). In particular, median parasite clearance time was extended in Cambodia for both treatment groups at 64.1 h for PA and 64.2 h for MQ + AS (Figure  [5](#F5){ref-type="fig"}B). In comparison, median parasite clearance time in Thailand was 31.7 h for PA and 38.7 h for MQ + AS (Figure  [5](#F5){ref-type="fig"}B). Day-28 PCR-corrected ACPR (ITT population) in the PA group in Cambodia was 89.3% (125/140) 95% CI 82.9, 93.9 and in Thailand was 93.3% (375/402) 95% CI 90.4, 95.5. For MQ + AS group, day-28 PCR-corrected ACPR (ITT population) was 93.0% (66/71) 95% CI 84.3, 97.7 in Cambodia and 88.9% (176/198) 95% CI 83.7, 92.9 in Thailand.

![**Parasite clearance time for A) all centres; B) Cambodia*versus*Thailand.** Kaplan-Meier survival plot for the integrated efficacy analysis (intent-to-treat population).](1475-2875-12-70-5){#F5}

###### 

***Plasmodium falciparum*parasite and fever clearance times and proportion of patients with clearance on days 1, 2, and 3 (intent-to-treat population)**

  **Outcome**                             **PA**            **MQ + AS**           **AL**
  --------------------------------- ------------------- ------------------- -------------------
  **Parasite clearance**                                                              
  Patients with clearance,% (n/N)    93.7 (1923/2052)     88.2 (373/423)      97.5 (588/603)
  Median time to clearance, h              24.1                31.9                24.0
    Africa                                 23.9                23.9                24.0
    Asia                                   32.0                39.2                31.5
  Day 1 clearance,% (95% CI)         48.2 (46.2, 50.2)   33.7 (30.8, 36.8)   51.5 (48.5, 54.6)
  Day 2 clearance,% (95% CI)         89.9 (88.6, 91.1)   76.1 (72.5, 79.6)   92.0 (90.1, 93.6)
  Day 3 clearance,% (95% CI)         94.8 (93.9, 95.6)   84.2 (81.0, 87.1)   96.1 (94.9, 97.2)
  **Fever clearance**                                                                 
  Patients with clearance,% (n/N)    98.0 (1589/1621)     97.8 (348/356)      97.2 (450/463)
  Median time to clearance, h              15.5                15.8                14.0
    Africa                                  8.0                 8.0                 8.0
    Asia                                   16.0                16.0                16.0
  Day 1 clearance,% (95% CI)         81.9 (80.1, 83.6)   74.7 (70.8, 78.4)   84.1 (81.2, 86.8)
  Day 2 clearance,% (95% CI)         95.8 (94.9, 96.6)   92.2 (89.8, 94.3)   96.7 (95.4, 97.8)
  Day 3 clearance,% (95% CI)         97.8 (97.1, 98.3)   95.3 (93.4, 96.8)   98.3 (97.5, 99.0)

PA, pyronaridine-artesunate; MQ + AS, mefloquine plus artesunate; AL, artemether-lumefantrine; NA, not available.

Percentages are based on available observations.

Median percentiles as well as confidence intervals and estimates of survival rates at Day 1, 2 and 3 were adjusted for study.

The majority of patients with *P. falciparum* had fever clearance by day 1 (Table  [6](#T6){ref-type="table"}). Median fever clearance time for *P. falciparum* in the ITT population was 15.5 h for PA, 15.8 h for MQ + AS and 14.0 h with AL (Table  [6](#T6){ref-type="table"}, Figure  [6](#F6){ref-type="fig"}). Fever clearance times were extended in Asia *versus* Africa for all treatments (Table  [6](#T6){ref-type="table"}).

![**Fever clearance time.** Kaplan-Meier survival plot for the integrated efficacy analysis (intent-to-treat population)](1475-2875-12-70-6){#F6}

*Plasmodium falciparum* gametocytes were present in 8.9% (276/3,078) of patients at baseline, and gradually decreased to 0% or near 0% in all treatment groups by the end of the study (Figure  [7](#F7){ref-type="fig"}).

![**Proportion of patients with*Plasmodium falciparum*gametocytes.** Integrated efficacy analysis (intent-to-treat population). Two-sided 95% confidence intervals (Wald) were adjusted for study.](1475-2875-12-70-7){#F7}

To further investigate *P. falciparum* gametocyte carriage, data for the two studies that recruited both adults and children (SP-C-004-06 and SP-C-005-06) were reanalysed to calculate the log~10~ AUC for gametocyte density (Figure  [8](#F8){ref-type="fig"}). In study SP-C-004-06, in patients who had gametocytes at baseline, median log~10~ \[AUC gametocyte density\] was 3.1 (range 0.1 to 4.4) in the PA group (n = 81) and 2.5 (range −0.2 to 4.2) in the MQ + AS group (n = 49) (Figure  [8](#F8){ref-type="fig"}A). In study SP-C-005-06, in patients who had gametocytes at baseline, median log~10~ \[AUC gametocyte density\] was 2.5 (range −0.8 to 4.8) in the PA group (n = 66) and 2.1 (−0.3 to 3.6) in the AL group (n = 22) (Figure  [8](#F8){ref-type="fig"}C). In patients with no gametocytes at baseline, but who had post-baseline gametocytes, in study SP-C-004-06, median log~10~ \[AUC gametocyte density\] was 2.1 (range 0.43 to 3.65) in the PA group (n = 64) and 1.4 (range 0.22 to 3.4) in the MQ + AS group (n = 17) (Figure  [8](#F8){ref-type="fig"}B). In study SP-C-005-06, median log~10~ \[AUC gametocyte density\] was 0.9 (range −0.5 to 3.0) in the PA group (n = 67) and 0.5 (−0.5 to 3.2) in the AL group (n = 25) (Figure  [8](#F8){ref-type="fig"}D).

![***Plasmodium falciparum*gametocyte density over time.A)** Study SP-C-004-06 comparing pyronaridine-artesunate to mefloquine + artesunate gametocyte density over time in patients with baseline gametocytes and **B)** no gametocytes at baseline and post-baseline gametocytes. **C)** Study SP-C-005-06 comparing pyronaridine-artesunate to artemether-lumefantrine gametocyte density over time in patients with baseline gametocytes and **D)** no gametocytes at baseline and post-baseline gametocytes. All data are for the intent-to-treat population.](1475-2875-12-70-8){#F8}

Discussion
==========

The integrated safety analysis included 2,815 adults and children treated with PA for uncomplicated *P. falciparum* or *P. vivax* infection. The PA group was well balanced for baseline clinical and demographic characteristics with respect to the combined comparator group. The safety profile for PA in this analysis was similar to that reported for pyronaridine and artemisinin monotherapy \[[@B21],[@B32]-[@B35]\]. Comparator safety profiles were also consistent with previous reports for MQ + AS \[[@B36]-[@B42]\], AL \[[@B25],[@B43]-[@B46]\] and CQ \[[@B23],[@B47],[@B48]\].

Overall, PA and comparators were generally well tolerated. Although the nature and incidence of adverse events were generally similar between PA and comparators overall, dizziness was more common with MQ + AS (6.6%) and myalgia with CQ (9.2%) than with PA (1.4% and 3.8%, respectively) (Table  [4](#T4){ref-type="table"}). Serious adverse events were uncommon in all treatment groups (0--0.7%). For PA, only one patient had serious adverse events thought to be related to drug treatment; hepatic enzymes increased and incomplete abortion.

The only significant laboratory finding in the PA group was a mean increase in ALT and AST on days 3 and 7, compared with decreases in these enzymes for comparators (Figure  [2](#F2){ref-type="fig"}). As a result of this signal, an Independent Data Monitoring Committee (IDMC) comprising six members, including three experts in hepatotoxicity, examined the data from all of the studies. Increased transaminases have been observed consistently across all the Phase II/III PA clinical studies and two (of four) of the completed Phase I studies. When they occurred, rises in transaminases peaked by day 7 and levels had normalized or were decreasing by day 28 with no instances of Grade 3 or 4 toxicity at this time point. Increased transaminases were associated rarely with rises in total bilirubin, which was often high at baseline and subsequently fell during treatment. Overall, 0.2% (7/2,815) of patients in the PA group and 0.3% (2/603) in the AL group had ALT and/or AST \>3x the upper limit of normal (ULN) plus peak total bilirubin \>2xULN; one of these patients in the PA group had elevated ALP which precluded them as a Hy's law case. Importantly, no patients had any clinical sequelae related to these liver function changes and as a result the IDMC concluded that whilst PA treatment is associated with transient elevated transaminases, the early onset (day 3--7) and rapid resolution are consistent with a direct low-level toxicity. Therefore, as PA is dosed for only three days, the risk of progressive liver injury is small. Additional studies are ongoing in healthy volunteers and in patients to assess the hepatic safety profile of PA when the treatment is administered more than once.

Electrocardiograph results did not suggest any cardiac safety concerns with PA. As would be expected, prolonged QT interval was uncommon with PA (0.07%) but occurred more frequently with the quinoline derivatives MQ (0.7%) and particularly CQ (2.7%) \[[@B49]\]. Bradycardia was observed as an adverse event in 1.1% of patients receiving PA and 0.8% with AL. However, the finding of bradycardia in a young and otherwise fit population is likely to be associated with the resolution of the tachycardia associated with fever as decreases in mean heart rate were noted across all treatment groups and have been observed in other studies of anti-malarial therapy as patients become afebrile and they return to their normal baseline heart rate \[[@B33],[@B50]-[@B52]\].

For the treatment of uncomplicated *P. falciparum* in children and adults, there was no difference between PA and comparators for day-28 PCR-corrected ACPR for the ITT or PP analyses (Figure  [3](#F3){ref-type="fig"}). This reflects results from the three *P. falciparum* Phase III studies in which non-inferiority of PA day 28 PCR-corrected ACPR (PP population) was demonstrated *versus* MQ + AS or AL \[[@B15],[@B22],[@B25]\]. Sub-group analysis showed similar day-28 PCR-corrected ACPR (ITT population) for PA by region, age group, gender, weight, previous malaria, malaria in the last 12 months, and baseline parasitemia *versus* efficacy with PA overall (Table  [5](#T5){ref-type="table"}).

Kaplan-Meier analysis of the integrated efficacy analysis indicated a *P. falciparum* recrudescence rate for PA intermediate between the comparators (Figure  [4](#F4){ref-type="fig"}A). For individual studies, recrudescence rate over the 42-day study period was marginally higher with PA *versus* MQ + AS (*P* = .049) in SP-C-004-06 and similar *versus* AL (*P* = .90) in SP-C-005-06 and in the paediatric study SP-C-007-07 (*P* = .53) \[[@B15],[@B22],[@B25]\]. Similarly, Kaplan-Meier analysis of the integrated efficacy analysis indicated a *P. falciparum* re-infection rate for PA intermediate between the comparators (AL highest, MQ + AS lowest) (Figure  [4](#F4){ref-type="fig"}B). However, in the individual Phase III studies, re-infection rate was higher with MQ + AS than PA at day 28 (*P* = .04), and similar at day 42 (*P* = .17) \[[@B15]\]. One difference in the integrated analysis was that there were more patients in the PA group who where under 18 years of age than in the MQ + AS group and this may have increased the re-infection rate for PA relative to MQ + AS. In support of this, in the Phase III study of PA *versus* AL that comprised mostly adults (SP-C-005-06), PA had a lower re-infection rate than AL (day 28 *P* = .004, day 42 *P* = .007) \[[@B25]\], but this difference was not evident in the paediatric PA *versus* AL study (SP-C-007-07) (*P* = .77) \[[@B22]\]. In the integrated analysis, re-infection rate was lower with PA than AL and the patients in the AL group tended to be younger. An alternative explanation is that there were differences in transmission rates between the treatment groups given the imbalance in Asian *versus* African centres in the integrated analysis.

In the integrated analysis, the *P. falciparum* parasite clearance rate was 24.1 h with PA and 32.9 h with MQ + AS (Figure  [5](#F5){ref-type="fig"}A, Table  [6](#T6){ref-type="table"}). However, this was not seen in the comparative Phase III trial of these treatments in which median parasite clearance time was approximately 32 h in both arms (*P* = .08) \[[@B15]\]. This is probably because of the greater proportion of patients from Africa in the PA group *versus* the MQ + AS group in the integrated analysis; median parasite clearance rates were longer in Asia than Africa for all comparators (Table  [6](#T6){ref-type="table"}). In particular, in Cambodia parasite clearance times were extended for PA and MQ + AS to around 64 h (Figure  [5](#F5){ref-type="fig"}B). However, this did not seem to affect the day-28 PCR-corrected ACPR (ITT population) between Cambodia and Thailand for either PA or MQ + AS. Extended parasite clearance times indicate the presence of artemisinin resistance and the results presented here are consistent with other reports from the Cambodia--Thailand border area \[[@B8]-[@B14],[@B53]\]. For example, mean parasite clearance times of around 65 h have been reported for artemisinin-piperaquine, dihydroartemisinin-piperaquine and AL in this region \[[@B13]\].

Parasite clearance times were similar between PA and AL in the integrated analysis (Figure  [5](#F5){ref-type="fig"}A). However, in the individual studies of PA *versus* AL, parasite clearance was faster with PA (*P* = .02) in study SP-C-007-07 conducted in children, and in study SP-C-005-06 including mostly adults (*P* \< .001) \[[@B22],[@B25]\]. As above, these differences are probably explained by the longer parasite clearance times in Asian *versus* African centres, there being a relative lack of patients recruited from Asian centres in the AL group compared with the PA group in the integrated analysis.

Fever clearance time for PA in the integrated analysis was approximately intermediate between AL (fastest) MQ + AS (slowest) (Figure  [6](#F6){ref-type="fig"}). However, in the individual Phase III studies, fever clearance times were shorter with PA *versus* AL in the paediatric study (*P* = .049) and there was no difference in the study conducted *versus* AL mostly in adults (*P* = .55) \[[@B22],[@B25]\]. This again probably reflects the greater proportion of patients recruited from Asian centres in the PA and MQ + AS groups *versus* the AL group in the integrated analysis.

In the integrated analysis, it appeared that AL more rapidly eradicated gametocytes *versus* PA and MQ + AS (Figure  [7](#F7){ref-type="fig"}). However, this is also probably explained by the difference in baseline populations. To investigate further, gametocytes carriage was analysed in the two studies that enrolled both adults and children \[[@B15],[@B25]\], using log~10~ AUC \[gametocyte density\] \[[@B54],[@B55]\]. In patients with baseline gametocytes, MQ + AS did appear to more rapidly reduce gametocyte carriage *versus* PA, though in patients with no gametocytes at baseline PA appeared to more effectively suppress gametocyte emergence (Figure  [8](#F8){ref-type="fig"}). There appeared to be no differences between AL and PA in respect to gametocyte clearance or suppression.

Children are the most important target group for anti-malarial therapy, having reduced immunity and consequently poorer outcomes. Despite this, until recently paediatric ACT formulations have been generally lacking \[[@B56]\]. Paediatric formulations are easier to administer and may be better tolerated, particularly in terms of vomiting, which may affect anti-malarial drug levels \[[@B57]\]. A granule formulation was included in the PA development plan to ensure early availability after drug registration. For the primary efficacy outcome used in the Phase III studies -- day-28 PCR-corrected ACPR -- the granule and tablet formulation had similar efficacy in this analysis. Efficacy outcomes at day 42 were also similar for the two pyronaridine-artesunate formulations.

For the efficacy analysis, this report is concerned with the integrated analysis of the PA Phase III *P. falciparum* clinical trials. However, the efficacy of PA in *P. vivax* has also been evaluated in one Phase III study in adults and children \[[@B23]\]. In summary, for the primary outcome -- the day-14 crude cure rate (PP population) -- PA efficacy was 99.5%, (217/218; 95% CI 97.5, 100). This was non-inferior to CQ 100% efficacy (209/209; 95% CI 98.3, 100); treatment difference −0.5% (95% CI −2.6, 1.4). Non-inferiority of PA to CQ was maintained throughout follow-up (days 21, 28, 35 and 42) \[[@B23]\]. Additional clinical trials will report PA safety and efficacy in young children with *P. vivax* malaria and PA efficacy in areas of chloroquine-resistant *P. vivax*.

Conclusions
===========

Overall, PA was well tolerated with a similar adverse event profile to comparators. Although PA was associated with transient increases in transaminases in a relatively small proportion of patients, there was no indication of a risk of progressive liver injury. Pyronaridine-artesunate efficacy against *P. falciparum* was consistently high regardless of geographical region, patient age, gender, or degree of parasitaemia. Against *P. vivax*, PA had efficacy at least as good as CQ but with more rapid parasite and fever clearance and a lower parasite re-emergence rate. Importantly, PA has been developed to have a specific paediatric granule formulation available, shown to have equivalent pharmacokinetics and efficacy to the tablet formulation \[[@B24]\]. Initially, PA will be used in areas of low endemicity and where cases of artemisinin resistance have been reported with deployment to areas of high endemicity once further data on repeated treatment with PA have been obtained. Pyronaridine-artesunate is a useful new ACT and should be a valuable addition to anti-malarial treatment programmes.
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